AstraZeneca, Pfizer vaccines effective against delta COVID-19 variants: Study

AstraZeneca, Pfizer vaccines are widely effective against delta and kappa variants of Covid (File)

The COVID-19 vaccines made by AstraZeneca and the Pfizer-BioNtech alliance are widely effective against delta and kappa variants of COVID-19, which have been identified for the first time in India, according to a scientific study. who gave a relentless push to deliver the shots. .

The study, published in the journal Cell by Oxford University researchers, examined the ability of antibodies in the blood of people who were vaccinated with two-shot regimens to neutralize the highly infectious delta and kappa variants, a statement said. was.

Referring to the delta and kappa variants by commonly used codes, the paper said, “There is no widespread evidence that the current generation of vaccines will provide protection against the B1.617 lineage.”

However, the concentration of neutralizing antibodies in the blood was somewhat reduced, which can lead to some infections, he cautioned.

Last week, an analysis by Public Health England (PHE) showed that vaccines made by Pfizer Inc. and AstraZeneca offer more than 90% higher protection against hospitalization than the delta version.

“We are encouraged to look at published non-clinical results from Oxford and these data, together with a recent early real-world analysis from Public Health England, provide us with a positive indication that our vaccine delta version could have significant ramifications,” AstraZeneca executive Mene Pangalos said in a separate statement.

The chief scientist of the World Health Organization said on Friday that the delta variant is becoming the dominant version of the disease globally.

The Oxford researchers also analyzed reinfection patterns in people who had previously had COVID-19. The risk of reinfection with the delta variant appeared to be particularly high in previously infected individuals from the beta and gamma lineage that emerged in South Africa and Brazil.

Conversely, a previous infection with alpha, or B117, the variant first detected in the UK, provided “proper” cross-protection against all forms of concern, lending itself as a template upon which to follow. Generational vaccines can be molded.

“B117 may be a candidate for new types of vaccines to provide broad protection,” the researchers said.

(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)

.

LEAVE A REPLY

Please enter your comment!
Please enter your name here